Spark's vault provided $408.33 million in USD Coin (USDC) to Morpho's cbBTC/USDC lending market on Base, accounting for 23% of the total USDC supply in the pool as of October 20. This significant allocation influences the liquidity available for borrowers and lenders in the market, which has about $1.8 billion in total size and $1.59 billion in outstanding loans. The market allows borrowers to take USDC loans using Coinbase Wrapped Bitcoin (cbBTC) as collateral, with a liquidation threshold set at 86% loan-to-value. Launched in September 2024, this market is part of Coinbase's crypto-backed USDC loan offerings powered by Morpho on Base.
The news about Spark supplying $408 million in USDC to Morpho’s Base market is presented here with Pluang's market data for context. For readers following major cryptocurrencies, 44 out of 50 rose today as of Oct 21, 2026 05:11 WIB. Notably, COMP gained 23.17% to Rp475.589 with a typical hold time of 98 days and a buy-dominant order activity of 68%, contrasting with THETA which fell 100% on sell orders despite an 11.62% price rise to Rp3.746, and BAL rose 11.14% to Rp16.297 with an 85-day hold time.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
